基础医学与临床 ›› 2024, Vol. 44 ›› Issue (1): 108-113.doi: 10.16352/j.issn.1001-6325.2024.01.0108

• 短篇综述 • 上一篇    下一篇

诱导肝星状细胞铁死亡治疗肝纤维化的研究进展

孙立杰1, 郝丹丹2*   

  1. 1.赤峰学院附属医院 普外科,内蒙古 赤峰 024005;
    2.赤峰学院 基础医学院 生理学教研室,内蒙古 赤峰 024000
  • 收稿日期:2023-05-15 修回日期:2023-10-31 出版日期:2024-01-05 发布日期:2023-12-25
  • 通讯作者: *:hdd2011yx@163.com
  • 基金资助:
    内蒙古自然科学基金 (2022MS08032)

Progress of researches on inducing hepatic stellate cell ferroptosis for treatment of liver fibrosis

SUN Lijie1, HAO Dandan2*   

  1. 1. Department of General Surgery, the Affiliated Hospital of Chifeng College, Chifeng 024005;
    2. Department of Physiology, School of Basic Medical Science,Chifeng University, Chifeng 024000, China
  • Received:2023-05-15 Revised:2023-10-31 Online:2024-01-05 Published:2023-12-25
  • Contact: *:hdd2011yx@163.com

摘要: 铁死亡是一种铁依赖性的调节性细胞死亡形式,通过使肝星状细胞(HSC)失活、抑制肝纤维化和诱导肝细胞死亡参与肝纤维化发病机制,药物诱导HSC铁死亡治疗肝纤维化。探索诱导HSC铁死亡成为治疗肝纤维化的新靶点。

关键词: 肝纤维化, 肝星状细胞, 铁死亡

Abstract: Emerging evidence suggests that ferroptosis, an iron-dependent form of regulated cell death, plays a critical role in the genesis of liver fibrosis through inducing hepatic stellate cell (HSC) ferroptosis to inhibit liver fibrosis or inducing hepatic ferroptosis to potentiates liver fibrosis. Pharmacologically targeting at ferroptosis with its inducers can slow down the progression of liver fibrosis in vitro and in vivo model. This review suggests that pharmacological induction of HSC ferroptosis might be used as a potential novel targeted therapy for the treatment of liver fibrosis.

Key words: liver fibrosis, hepatic stellate cell, ferroptosis

中图分类号: